🟢 Tvardi Therapeutics is trading 6.1% up in pre-market with no clear catalyst identified

Tvardi Therapeutics is trading 6.14% higher at $1.21 in pre-market; no clear company-specific catalyst was identified for the October 6, 2026 move.

• The supplied pre-market price compares with a prior close of $1.14.
• Its latest listed announcement was a September 24 preclinical ulcerative-colitis update; no October 5 or 6 announcement appears in its press-release listing.
• Broader markets are higher, but supplied index gains are below the 0.5% threshold for attributing the move to market sentiment.